Teacher Retirement System of Texas Acquires 2,755 Shares of Twist Bioscience Co. (NASDAQ:TWST)

Teacher Retirement System of Texas increased its holdings in Twist Bioscience Co. (NASDAQ:TWST) by 18.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,357 shares of the company’s stock after acquiring an additional 2,755 shares during the quarter. Teacher Retirement System of Texas’ holdings in Twist Bioscience were worth $807,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently bought and sold shares of TWST. Wilmington Savings Fund Society FSB bought a new position in shares of Twist Bioscience during the third quarter valued at approximately $34,000. Van ECK Associates Corp increased its position in Twist Bioscience by 56.4% during the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock valued at $34,000 after buying an additional 267 shares in the last quarter. US Bancorp DE increased its position in Twist Bioscience by 72.0% during the 4th quarter. US Bancorp DE now owns 1,436 shares of the company’s stock valued at $67,000 after buying an additional 601 shares in the last quarter. Beaird Harris Wealth Management LLC purchased a new position in Twist Bioscience during the third quarter valued at $95,000. Finally, KBC Group NV boosted its holdings in Twist Bioscience by 71.4% in the fourth quarter. KBC Group NV now owns 2,942 shares of the company’s stock worth $137,000 after acquiring an additional 1,226 shares in the last quarter.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on TWST. Wolfe Research began coverage on Twist Bioscience in a report on Friday, December 13th. They set an “outperform” rating and a $60.00 price target for the company. Barclays set a $58.00 target price on shares of Twist Bioscience and gave the stock an “overweight” rating in a report on Monday, February 3rd. Scotiabank reiterated an “outperform” rating on shares of Twist Bioscience in a report on Tuesday, February 4th. JPMorgan Chase & Co. raised their price target on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a research report on Tuesday, February 4th. Finally, Robert W. Baird upped their price objective on Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a research report on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $54.40.

Insider Activity at Twist Bioscience

In related news, CFO Adam Laponis sold 5,886 shares of the business’s stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $43.26, for a total transaction of $254,628.36. Following the completion of the transaction, the chief financial officer now directly owns 110,096 shares in the company, valued at approximately $4,762,752.96. The trade was a 5.07 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Robert Chess sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $50.00, for a total transaction of $250,000.00. Following the sale, the director now owns 16,641 shares in the company, valued at approximately $832,050. The trade was a 23.10 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 33,799 shares of company stock worth $1,593,944. 3.01% of the stock is owned by company insiders.

Twist Bioscience Price Performance

NASDAQ TWST opened at $40.36 on Friday. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62. Twist Bioscience Co. has a 1-year low of $27.41 and a 1-year high of $60.90. The stock has a market capitalization of $2.41 billion, a price-to-earnings ratio of -11.94 and a beta of 2.15. The business’s fifty day moving average price is $45.15 and its 200-day moving average price is $45.36.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.09. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The business had revenue of $88.70 million for the quarter, compared to analysts’ expectations of $86.96 million. During the same period last year, the firm posted ($0.75) earnings per share. The business’s revenue for the quarter was up 24.1% on a year-over-year basis. On average, equities analysts predict that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.